Immunotherapy plus TIPS for liver cancer with blocked portal vein
Treatments studied
Part of Cancer, Digestive system clinical trials.
This study tests whether adding the immunotherapy drug cadonilimab (and a related treatment plan) plus TIPS can help people with advanced liver cancer that has a tumor clot causing portal vein pressure problems. It aims to improve disease control while managing the circulation pressure in the liver.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You freely agree to join and sign an informed consent form
- You are age 18 to 75, and you have confirmed hepatocellular carcinoma (liver cancer)
- Your cancer has at least one measurable spot that is not treated locally (for example, not treated right at the spot before starting)
- Your liver function is still adequate (Child-Pugh score 13 or less)
- You have advanced stage liver cancer with a tumor clot that is causing portal vein pressure problems
- You have not had targeted therapy or immunotherapy before, and your general strength is ECOG 0 to 1
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This trial tests a combination of immunotherapy (sintilimab), a targeted anti-angiogenic drug (bevacizumab biosimilar), and liver-directed therapies (TACE-HAIC) before and after surgery for hepatocellular carcinoma that has spread to the portal vein. The goal is to see if this approach improves outcomes for patients with advanced but resectable liver cancer.
This trial tests a combination of two drugs (lenvatinib and toripalimab, a type of immunotherapy) plus a special chemotherapy infusion directly into the liver artery for people with advanced liver cancer that has not been treated before. The goal is to see if adding the immunotherapy helps shrink tumors better than the standard combination.
This trial combines a procedure called TIPS (which helps relieve pressure in the liver) with two drugs—lenvatinib (a targeted therapy) and a PD-1 inhibitor (an immunotherapy)—for people with advanced liver cancer that has spread into the main vein of the liver. It aims to see if this combination can help control the cancer and improve symptoms.
This trial tests a combination of two treatments for advanced liver cancer: TACE (a procedure that blocks the blood supply to the tumor) and an anti-PD-1 antibody (a type of immunotherapy that helps your immune system fight cancer). The goal is to see if this combination works better than either treatment alone and to understand how it affects the immune system around the tumor.
This trial tests whether combining radiation (IMRT) with two drugs—camrelizumab (an immunotherapy) and apatinib (a targeted therapy)—before surgery can help people with liver cancer that has spread to the main blood vessel of the liver (portal vein). The goal is to shrink the tumor and improve surgical outcomes.
This trial tests a combination of treatments for liver cancer that has spread to the main portal vein. It uses a special stent, radiation seeds, and targeted therapies to shrink the tumor and improve blood flow. This may help patients who haven't had certain prior treatments.
Hear when a new Hepatocellular Carcinoma trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.